Description

The global antifungal drugs market is set to increase by US$ 4.3 billion from 2022 to 2028, representing a compound annual growth rate (CAGR) of 4.1% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for antifungal drugs. The global antifungal drugs market is segmented on the basis of type, infection type, drug type, indication, and region. On the basis of type, the global antifungal drugs market has been segmented into prescription, OTC. Among these, the OTC segment was accounted for the highest revenue generator in 2021. By infection type, the global antifungal drugs market has been segmented into superficial, topical. Based on drug type, the global antifungal drugs market is categorized into echinocandins, polyenes, azoles, antimetabolites, others. The azoles segment held the largest share of the global antifungal drugs market in 2021 and is anticipated to hold its share during the forecast period. On the basis of indication, the global antifungal drugs market has been segmented into dermatophytosis, aspergillosis, candidiasis, others. In 2021, the aspergillosis segment made up the largest share of revenue generated by the antifungal drugs market. In terms of geography, the global antifungal drugs market has been segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global antifungal drugs market is highly competitive. The key players in the antifungal drugs market include Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Gilead Sciences Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the antifungal drugs market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: prescription, OTC
Infection type: superficial, topical
Drug type: echinocandins, polyenes, azoles, antimetabolites, others
Indication: dermatophytosis, aspergillosis, candidiasis, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global antifungal drugs market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Antifungal drugs market overview
Part 3. Market breakdown by type
– Prescription
– OTC
Part 4. Market breakdown by infection type
– Superficial
– Topical
Part 5. Market breakdown by drug type
– Echinocandins
– Polyenes
– Azoles
– Antimetabolites
– Others
Part 6. Market breakdown by indication
– Dermatophytosis
– Aspergillosis
– Candidiasis
– Others
Part 7. Market breakdown by region
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)
Part 8. Key companies
– Astellas Pharma Inc.
– Bausch Health Companies Inc.
– Bayer AG
– Dr. Reddy’s Laboratories Ltd.
– Galderma S.A.
– Gilead Sciences Inc.
– Janssen Pharmaceuticals, Inc.
– Merck & Co., Inc.
– Pfizer Inc.
– Teva Pharmaceutical Industries Ltd.
About StrategyHelix
Disclaimer